Amgen Insists US Biosimilars Market Is Working Well
Amgen insists that the initial response to the trastuzumab and bevacizumab biosimilars it has launched in the US, as well as the pressure it is feeling from competition to its Neulasta pegfilgrastim original, show that the US biosimilars market is functioning well. Therefore, the firm feels, structural interventions are unnecessary.
You may also be interested in...
The latest salvo has been fired in a fierce debate between US healthcare experts on whether US policymakers and payers should give up on biosimilars in favor of price controls on original biologics.
Coherus’ manufacturing process for its Udenyca pegfilgrastim biosimilar does not infringe a US purification patent held by Amgen, the US Court of Appeals has confirmed.
Legality Of J&J's Remicade Contracting Depends On Share Of Biosimilar Market Foreclosed, Court Rules
Court denies J&J's motion to dismiss Pfizer's antitrust suit, saying discovery will reveal whether Pfizer has offered more competitive pricing for its Inflectra biosimilar and if there are alternative causes for Pfizer's inability to gain market share.